EA200801833A1 - Способы получения кристаллических форм дулоксетина гидрохлорида - Google Patents

Способы получения кристаллических форм дулоксетина гидрохлорида

Info

Publication number
EA200801833A1
EA200801833A1 EA200801833A EA200801833A EA200801833A1 EA 200801833 A1 EA200801833 A1 EA 200801833A1 EA 200801833 A EA200801833 A EA 200801833A EA 200801833 A EA200801833 A EA 200801833A EA 200801833 A1 EA200801833 A1 EA 200801833A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
hydrochloride
duloxethine
crystalline forms
obtaining crystalline
Prior art date
Application number
EA200801833A
Other languages
English (en)
Inventor
Антон Стимац
Наталия Зайц
Анамария Вайс
Рената Яксе
Рок Зупет
Original Assignee
Крка
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крка filed Critical Крка
Publication of EA200801833A1 publication Critical patent/EA200801833A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение также относится к способам получения формы А и формы Т, которые включают растворение дулоксетина гидрохлорида в конкретных растворителях и охлаждение раствора с получением кристаллов, которые высушивают.
EA200801833A 2006-02-17 2007-02-16 Способы получения кристаллических форм дулоксетина гидрохлорида EA200801833A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06003244A EP1820800A1 (en) 2006-02-17 2006-02-17 Crystalline forms of duloxetine hydrochloride and processes for their preparation
PCT/EP2007/001380 WO2007093439A1 (en) 2006-02-17 2007-02-16 Processes for the preparation of crystalline forms of duloxetine hydrochloride

Publications (1)

Publication Number Publication Date
EA200801833A1 true EA200801833A1 (ru) 2008-12-30

Family

ID=36754582

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801833A EA200801833A1 (ru) 2006-02-17 2007-02-16 Способы получения кристаллических форм дулоксетина гидрохлорида

Country Status (3)

Country Link
EP (3) EP1820800A1 (ru)
EA (1) EA200801833A1 (ru)
WO (1) WO2007093439A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100888A3 (en) 2005-12-05 2011-01-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of duloxetine hydrochloride
US20080027128A1 (en) * 2006-05-23 2008-01-31 Santiago Ini Duloxetine HCL polymorphs
GB0612509D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612508D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612506D0 (en) 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
WO2008107911A2 (en) 2007-03-05 2008-09-12 Lupin Limited Novel process for preparation of duloxetine hydrochloride
US9358213B2 (en) * 2007-04-20 2016-06-07 Wockhardt Limited Pharmaceutical compositions of duloxetine
WO2009010238A2 (en) * 2007-07-13 2009-01-22 Synthon B.V. Duloxetine formulations
JP2011510024A (ja) * 2008-01-25 2011-03-31 アルファファーム ピーティーワイ リミテッド デュロキセチンの遅延放出医薬組成物
EP2133072A1 (en) 2008-06-13 2009-12-16 KRKA, D.D., Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
WO2009150238A2 (en) * 2008-06-13 2009-12-17 Krka, D.D. Novo Mesto Gastro-resistant pharmaceutical oral compositions comprising duloxetine or its pharmaceutically acceptable derivatives
CZ304602B6 (cs) * 2009-09-02 2014-07-30 Zentiva, K. S. Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
CA2799007A1 (en) * 2010-05-25 2011-12-01 Hetero Research Foundation Oral pharmaceutical composition of duloxetine
CN103626735A (zh) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 一种盐酸度洛西汀晶型及其制备方法
KR102242670B1 (ko) * 2014-01-09 2021-04-20 일동제약(주) 둘록세틴이 함유된 안정한 다중코팅 정제 조성물
CN113603673A (zh) * 2020-11-16 2021-11-05 上海中西三维药业有限公司 一种盐酸度洛西汀的晶型、其制备方法及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
AU2003263585A1 (en) 2003-08-25 2005-03-10 Hetero Drugs Limited Amorphous duloxetine hydrochloride
WO2005065726A1 (en) 2003-12-30 2005-07-21 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof

Also Published As

Publication number Publication date
EP1984346A1 (en) 2008-10-29
EP1820800A1 (en) 2007-08-22
EP2308864A1 (en) 2011-04-13
WO2007093439A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
EA200801833A1 (ru) Способы получения кристаллических форм дулоксетина гидрохлорида
LTPA2018501I1 (lt) Heterocikliniai amido dariniai, naudingi kaip mikrobiocidai
EA200900793A1 (ru) Способ получения эзетимиба и его производных
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201070186A1 (ru) Способы и соединения, предназначенные для получения ингибиторов котранспортера натрий-глюкозы 2 типа
ATE491700T1 (de) KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-
EA201171200A1 (ru) Полиморфы элтромбопага и солей элтромбопага, а также способы их получения
SMT201400142B (it) Composti di N-(1H-indazol-4-il) immidazo[1,2-A]piridin-3-carbossammide sostituita come inibitori di cfms
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
EA201000883A1 (ru) Производные индолинона и способ их получения
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
BRPI0820689A2 (pt) processo de produção de um derivado de indolinona
EA201000950A1 (ru) Азолилметилоксираны, их применение, а также содержащие их средства
NO20053676D0 (no) Crystallisation Process
ATE504556T1 (de) Herstellung von natriumdiformiat
NO20053687D0 (no) Crystallisation Process.
EA201270535A1 (ru) Пуриновые производные, применимые в качестве ингибиторов hsp90
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
EA201071120A1 (ru) Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
EA201070228A1 (ru) Тразодон и гидрохлорид тразодона в очищенной форме
ATE512132T1 (de) Hydrochloridsalz von 5-ä3-(3- hydroxyphenoxy)azetidin-1-ylü-5-methyl-2,2- diphenylhexanamid
EA201892052A1 (ru) Способ получения органических соединений
EA200700807A1 (ru) Новые циклические и ациклические пропеноны для лечения заболеваний цнс
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия